<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986778</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-195</org_study_id>
    <nct_id>NCT00986778</nct_id>
  </id_info>
  <brief_title>Entecavir Plus Adefovir in Lamivudine-Resistant Patients</brief_title>
  <official_title>A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity
      compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in
      Chinese adults with lamivudine-resistant chronic hepatitis B infection
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business Objectives Changed
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with HBV DNA &lt; 50 IU/mL at W48</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patient with HBV DNA &lt; 50 IU/mL at W 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction of HBV DNA at W 48 &amp; 96</measure>
    <time_frame>Week 48 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with ALT normalization at W 48 &amp; 96</measure>
    <time_frame>Week 48 &amp; Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieved HBeAg loss, seroconversion, HBsAg loss and seroconversion at W48 &amp; 96</measure>
    <time_frame>Week 48 &amp; 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Week 48 and Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance</measure>
    <time_frame>Week 48 &amp; Week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Lamivudine plus Adefovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir plus Adefovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response</description>
    <arm_group_label>Lamivudine plus Adefovir</arm_group_label>
    <other_name>Heptotin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response</description>
    <arm_group_label>Entecavir</arm_group_label>
    <arm_group_label>Entecavir plus Adefovir</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir</intervention_name>
    <description>Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response</description>
    <arm_group_label>Lamivudine plus Adefovir</arm_group_label>
    <arm_group_label>Entecavir plus Adefovir</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CHB HBeAg(+) Subject with Lamivudine treatment history must have LVDr substitution at
             rtM204V/I

          -  Naïve to nucleoside/nucleotide analogues except for LVD

          -  HBV DNA &gt; 17,200 IU/mL

          -  Compensated liver function

          -  Serum ALT &lt;10 × ULN

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Evidence of decompensated cirrhosis

          -  Coinfection with HIV, hepatitis C virus (HCV), or hepatitis D virus (HDV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

